Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab govitecan plus chemoimmunotherapy in advanced TNBC
NCT04927884Phase 2Terminated
- Sponsor
- ImmunityBio, Inc.
- Start
- Sep 2021
- Primary completion
- Sep 2022
- Modality
- Gene Editing, Gene Silencing, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nogapendekin alfa inbakicept and PD-L1 t-haNK in triple-negative breast cancer (TNBC), sponsored by ImmunityBio, Inc. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events up to 65 weeks and Objective Response Rate up to 51 weeks. Started Sep 2021; status: terminated.
02
Drugs
nogapendekin alfa inbakiceptPD-L1 t-haNK
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04927884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04927884.